$38.14-1.07 (-2.73%)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Liquidia Corporation in the Healthcare sector is trading at $38.14. The stock is currently 18% below its 52-week high of $46.67, remaining 23.6% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why LQDA maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...
Recently, Liquidia Corporation was highlighted as the top pick on billionaire Tom Steyer’s list of stocks with major upside potential, amid rapid real‑world uptake of its dry‑powder treprostinil therapy YUTREPIA for pulmonary hypertension and management commentary outlining a path toward a US$1.00 billion franchise by 2027. An interesting angle for investors is that this outside endorsement aligns with management’s own growth ambitions, underscoring how confidence in YUTREPIA’s commercial...
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Liquidia Corporation (NASDAQ:LQDA) ranks 1st on this list. Liquidia Corporation (NASDAQ:LQDA) first appeared in the 13F portfolio of Farallon Capital in the second quarter of 2020. Back then, this position comprised 1.8 million shares. The fund sold off this stake before the […]
This drug stock is testing a moving average in a base. This biopharma name has a patented technology to administer its drug.
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Class A investment in Laughing Water Capital returned approximately -4.5% net of all fees and expenses in the first quarter of 2026. The SP500TR and R2000 returned -4.3% and 0.9% respectively, during the […]
Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its core market.